Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of Rifaximin on Visceral Hypersensitivity in Irritable Bowel Syndrome

Trial Profile

Effects of Rifaximin on Visceral Hypersensitivity in Irritable Bowel Syndrome

Recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Oct 2018

At a glance

  • Drugs Rifaximin (Primary)
  • Indications Irritable bowel syndrome
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Oct 2018 Planned End Date changed from 1 Mar 2019 to 1 Jul 2019.
    • 08 Oct 2018 Planned primary completion date changed from 1 Mar 2019 to 1 Jul 2019.
    • 08 Oct 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top